JP4371179B2 - 系列限定ニューロン前駆体 - Google Patents
系列限定ニューロン前駆体 Download PDFInfo
- Publication number
- JP4371179B2 JP4371179B2 JP50743099A JP50743099A JP4371179B2 JP 4371179 B2 JP4371179 B2 JP 4371179B2 JP 50743099 A JP50743099 A JP 50743099A JP 50743099 A JP50743099 A JP 50743099A JP 4371179 B2 JP4371179 B2 JP 4371179B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- neuron
- ncam
- culture
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002243 precursor Substances 0.000 title claims description 133
- 210000002569 neuron Anatomy 0.000 title claims description 111
- 210000004027 cell Anatomy 0.000 claims description 647
- 238000000034 method Methods 0.000 claims description 101
- 230000001537 neural effect Effects 0.000 claims description 73
- 230000004069 differentiation Effects 0.000 claims description 57
- 210000000130 stem cell Anatomy 0.000 claims description 52
- 210000001130 astrocyte Anatomy 0.000 claims description 34
- 210000004248 oligodendroglia Anatomy 0.000 claims description 28
- 230000004044 response Effects 0.000 claims description 24
- 230000012010 growth Effects 0.000 claims description 22
- 210000001161 mammalian embryo Anatomy 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 210000000276 neural tube Anatomy 0.000 claims description 21
- 210000004498 neuroglial cell Anatomy 0.000 claims description 21
- 238000000338 in vitro Methods 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 19
- 230000001605 fetal effect Effects 0.000 claims description 19
- 230000035755 proliferation Effects 0.000 claims description 18
- 230000001953 sensory effect Effects 0.000 claims description 16
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 10
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 7
- 230000000394 mitotic effect Effects 0.000 claims description 7
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 5
- 241000287828 Gallus gallus Species 0.000 claims description 5
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 5
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 5
- 230000013020 embryo development Effects 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000010899 nucleation Methods 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 description 45
- 239000002858 neurotransmitter agent Substances 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 38
- 239000002609 medium Substances 0.000 description 33
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 31
- 241000700159 Rattus Species 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 27
- 210000000278 spinal cord Anatomy 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 25
- 102000004243 Tubulin Human genes 0.000 description 23
- 108090000704 Tubulin Proteins 0.000 description 23
- 230000002518 glial effect Effects 0.000 description 23
- 108090000742 Neurotrophin 3 Proteins 0.000 description 21
- 102000004230 Neurotrophin 3 Human genes 0.000 description 21
- 229940032018 neurotrophin 3 Drugs 0.000 description 21
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 19
- 229930002330 retinoic acid Natural products 0.000 description 19
- 229960001727 tretinoin Drugs 0.000 description 19
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 18
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 17
- 238000002054 transplantation Methods 0.000 description 17
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 16
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000011161 development Methods 0.000 description 16
- 230000018109 developmental process Effects 0.000 description 16
- 239000000543 intermediate Substances 0.000 description 16
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 15
- 239000004471 Glycine Substances 0.000 description 15
- 239000011575 calcium Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 102000008730 Nestin Human genes 0.000 description 14
- 108010088225 Nestin Proteins 0.000 description 14
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 14
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 14
- 210000005055 nestin Anatomy 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 102100036123 Far upstream element-binding protein 2 Human genes 0.000 description 13
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 13
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 13
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 13
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 210000002257 embryonic structure Anatomy 0.000 description 12
- 229930195712 glutamate Natural products 0.000 description 12
- 238000002372 labelling Methods 0.000 description 12
- 102100037362 Fibronectin Human genes 0.000 description 11
- 108010067306 Fibronectins Proteins 0.000 description 11
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 11
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 239000012981 Hank's balanced salt solution Substances 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 108090000189 Neuropeptides Proteins 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000003226 mitogen Substances 0.000 description 8
- 210000001428 peripheral nervous system Anatomy 0.000 description 8
- 210000001778 pluripotent stem cell Anatomy 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 229910001424 calcium ion Inorganic materials 0.000 description 7
- 230000032823 cell division Effects 0.000 description 7
- 238000003365 immunocytochemistry Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000000933 neural crest Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000009127 Glutaminase Human genes 0.000 description 6
- 108010073324 Glutaminase Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 6
- 102000004874 Synaptophysin Human genes 0.000 description 6
- 108090001076 Synaptophysin Proteins 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 102000014823 calbindin Human genes 0.000 description 6
- 108060001061 calbindin Proteins 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 210000002932 cholinergic neuron Anatomy 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 210000002161 motor neuron Anatomy 0.000 description 6
- 210000003757 neuroblast Anatomy 0.000 description 6
- 230000000926 neurological effect Effects 0.000 description 6
- 230000004031 neuronal differentiation Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 5
- 102000003797 Neuropeptides Human genes 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000001228 trophic effect Effects 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 4
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 4
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 4
- 102400001368 Epidermal growth factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011509 clonal analysis Methods 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 230000002964 excitative effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 3
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000012891 Ringer solution Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 3
- 230000000848 glutamatergic effect Effects 0.000 description 3
- 210000001362 glutamatergic neuron Anatomy 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000000626 neurodegenerative effect Effects 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000011536 re-plating Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 210000002504 synaptic vesicle Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- -1 vintronectin Proteins 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102000003693 Hedgehog Proteins Human genes 0.000 description 2
- 108090000031 Hedgehog Proteins Proteins 0.000 description 2
- 108010093096 Immobilized Enzymes Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 2
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940124277 aminobutyric acid Drugs 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000035 biogenic effect Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 229950004398 broxuridine Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 2
- 230000003371 gabaergic effect Effects 0.000 description 2
- 101150022753 galc gene Proteins 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001982 neural crest cell Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 230000009207 neuronal maturation Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000004116 schwann cell Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 210000002023 somite Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000025366 tissue development Effects 0.000 description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 239000010937 tungsten Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YIYCUMYWGOOSNU-FMZZOXHWSA-N 2-[[(2s)-1-[(2s,3s)-2-[[(2s,3r)-2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O YIYCUMYWGOOSNU-FMZZOXHWSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101100455868 Arabidopsis thaliana MKK2 gene Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101000890609 Bos taurus A-kinase anchor protein 5 Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 101100400452 Caenorhabditis elegans map-2 gene Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 241000027355 Ferocactus setispinus Species 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- 102000004327 Glycine dehydrogenase (decarboxylating) Human genes 0.000 description 1
- 108090000826 Glycine dehydrogenase (decarboxylating) Proteins 0.000 description 1
- 102000014015 Growth Differentiation Factors Human genes 0.000 description 1
- 108010050777 Growth Differentiation Factors Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101100163882 Mus musculus Ascl1 gene Proteins 0.000 description 1
- 101000735561 Mus musculus Protein-arginine deiminase type-6 Proteins 0.000 description 1
- RHEXWAQFMZCXIM-UHFFFAOYSA-N NC(N)=N.N=C=S.OC1=CC=CC=C1.ClC(Cl)Cl Chemical compound NC(N)=N.N=C=S.OC1=CC=CC=C1.ClC(Cl)Cl RHEXWAQFMZCXIM-UHFFFAOYSA-N 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 101000981993 Oncorhynchus mykiss Myelin proteolipid protein Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101000819238 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Gamma-aminobutyric acid-binding protein Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102100035596 Synaptoporin Human genes 0.000 description 1
- 101710146449 Synaptoporin Proteins 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 210000000604 fetal stem cell Anatomy 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000002165 glioblast Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 210000000461 neuroepithelial cell Anatomy 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000009237 prenatal development Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 108700019148 rat Ncl-ps1 Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000008189 vertebrate development Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/909,435 US6734015B1 (en) | 1997-07-04 | 1997-07-04 | Isolation of lineage-restricted neuronal precursors |
| US09/109,858 US6787353B1 (en) | 1997-07-04 | 1998-07-02 | Lineage-restricted neuronal precursors and methods of isolation |
| US08/909,435 | 1998-07-02 | ||
| US09/109,858 | 1998-07-02 | ||
| PCT/US1998/013875 WO1999001159A1 (en) | 1997-07-04 | 1998-07-03 | Lineage-restricted neuronal precursors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002515071A JP2002515071A (ja) | 2002-05-21 |
| JP2002515071A5 JP2002515071A5 (https=) | 2006-01-05 |
| JP4371179B2 true JP4371179B2 (ja) | 2009-11-25 |
Family
ID=26807446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50743099A Expired - Fee Related JP4371179B2 (ja) | 1997-07-04 | 1998-07-03 | 系列限定ニューロン前駆体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050003531A1 (https=) |
| EP (1) | EP1011732A4 (https=) |
| JP (1) | JP4371179B2 (https=) |
| KR (1) | KR20060002033A (https=) |
| AU (1) | AU755657B2 (https=) |
| CA (1) | CA2294737A1 (https=) |
| IL (1) | IL133799A0 (https=) |
| WO (1) | WO1999001159A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| AU689184B2 (en) | 1993-12-07 | 1998-03-26 | Genetics Institute, Llc | BMP-12, BMP-13 and tendon-inducing compositions thereof |
| US7544511B2 (en) | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
| ES2351170T3 (es) * | 1999-02-12 | 2011-02-01 | Stemcells California, Inc. | Poblaciones enriquecidas de células del sistema nervioso central. |
| EP1179046B1 (en) * | 1999-05-07 | 2006-03-08 | University Of Utah Research Foundation | Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells |
| DE19928210B4 (de) * | 1999-06-19 | 2005-08-18 | Neuroprogen Gmbh Leipzig | Neuronales Zellmaterial und Verfahren zu dessen Herstellung |
| AU7355500A (en) * | 1999-09-08 | 2001-04-10 | Genetics Institute Inc. | Bmp-9 compositions and methods for inducing differentiation of cholinergic neurons |
| EP1762244A1 (en) * | 1999-09-08 | 2007-03-14 | Genetics Institute, LLC | Bmp-9 compositions for inducing differentiation of cholinergic neurons |
| DK1223990T3 (da) | 1999-10-15 | 2004-11-29 | Inst Genetics Llc | Formuleringer af hyaluronsyre til tilförsel af osteogene proteiner |
| US20050042749A1 (en) | 2001-05-16 | 2005-02-24 | Carpenter Melissa K. | Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease |
| US7250294B2 (en) | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
| WO2001088104A2 (en) | 2000-05-17 | 2001-11-22 | Geron Corporation | Neural progenitor cell populations |
| WO2002026941A2 (en) * | 2000-09-29 | 2002-04-04 | Kooy Derek V D | Primitive neural stem cells and method for differentiation of stem cells to neural cells |
| US7226587B2 (en) | 2001-06-01 | 2007-06-05 | Wyeth | Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| CN101029302B (zh) * | 2001-06-21 | 2011-03-30 | 杰龙公司 | 用于治疗帕金森病的多巴胺能神经元和具有增殖能力的前体细胞 |
| US7285415B2 (en) | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| US20050101014A1 (en) | 2002-07-11 | 2005-05-12 | Keirstead Hans S. | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| US8293488B2 (en) | 2002-12-09 | 2012-10-23 | Neuralstem, Inc. | Method for screening neurogenic agents |
| US20040185429A1 (en) | 2002-12-09 | 2004-09-23 | Judith Kelleher-Andersson | Method for discovering neurogenic agents |
| EP1814979B1 (en) | 2004-11-17 | 2015-04-08 | Neuralstem, Inc. | Transplantation of human neural cells for treatment of neurodegenerative conditions |
| WO2008020815A1 (en) | 2006-08-15 | 2008-02-21 | Agency For Science, Technology And Research | Mesenchymal stem cell conditioned medium |
| CN101679951B (zh) * | 2007-04-17 | 2013-09-11 | 罗切斯特大学 | 端脑胶质限制性细胞群和相关组合物及方法 |
| EP2014768A1 (en) * | 2007-07-10 | 2009-01-14 | Innovalor AG | Neurons and methods for preparing them |
| SG188096A1 (en) | 2008-01-30 | 2013-03-28 | Geron Corp | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| JP2011514169A (ja) | 2008-03-17 | 2011-05-06 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 幹細胞培養のためのマイクロキャリア |
| US8669048B2 (en) | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
| WO2011011477A1 (en) | 2009-07-21 | 2011-01-27 | Abt Holding Company | Use of stem cells to reduce leukocyte extravasation |
| WO2011011500A1 (en) | 2009-07-21 | 2011-01-27 | Abt Holding Company | Use of stem cells to reduce leukocyte extravasation |
| DK2539436T3 (da) | 2010-02-25 | 2021-10-18 | Abt Holding Co | Modulering af makrofagaktivering |
| NZ623207A (en) | 2010-07-28 | 2014-12-24 | Neuralstem Inc | Methods for treating and/or reversing neurodegenerative diseases and/or disorders |
| WO2012048276A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
| PL2718416T3 (pl) | 2011-06-06 | 2020-05-18 | ReGenesys BVBA | Namnażanie komórek macierzystych w bioreaktorach włóknisto-kapilarnych |
| EP2970877B1 (en) | 2013-03-15 | 2018-07-25 | Wake Forest University Health Sciences | Neural progenitor cell differentiation |
| IL289870B2 (en) | 2013-04-12 | 2023-03-01 | Lafrancesca Saverio | Improving organs for transplantation |
| AU2014266935B2 (en) | 2013-04-30 | 2020-06-11 | Katholieke Universiteit Leuven | Cell therapy for myelodysplastic syndromes |
| WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
| WO2016064737A1 (en) | 2014-10-20 | 2016-04-28 | Neuralstem, Inc. | Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof |
| CN107408520B (zh) * | 2015-03-03 | 2022-02-25 | 卢茨·瑞布斯道克 | 检查系统 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087570A (en) * | 1988-05-10 | 1992-02-11 | Weissman Irving L | Homogeneous mammalian hematopoietic stem cell composition |
| US5411883A (en) * | 1989-12-26 | 1995-05-02 | Somatix Therapy Corporation | Proliferated neuron progenitor cell product and process |
| DK0594669T4 (da) * | 1991-07-08 | 2008-04-21 | Neurospheres Holdings Ltd | Neurale progenitorceller, som reagerer på vækstfaktorer og kan formeres in vitro |
| US5175103A (en) * | 1991-10-21 | 1992-12-29 | Trustees Of University Of Pennsylvania | Preparation of pure cultures of post-mitotic human neurons |
| US5589376A (en) * | 1992-07-27 | 1996-12-31 | California Institute Of Technology | Mammalian neural crest stem cells |
| KR950704476A (ko) * | 1992-10-28 | 1995-11-20 | 브렌드 레이놀즈 | 생물학적 인자 및 신경 간세포(biological factors and neural stem cells) |
| US5753505A (en) * | 1995-07-06 | 1998-05-19 | Emory University | Neuronal progenitor cells and uses thereof |
-
1998
- 1998-07-03 JP JP50743099A patent/JP4371179B2/ja not_active Expired - Fee Related
- 1998-07-03 EP EP98934255A patent/EP1011732A4/en not_active Withdrawn
- 1998-07-03 WO PCT/US1998/013875 patent/WO1999001159A1/en not_active Ceased
- 1998-07-03 IL IL13379998A patent/IL133799A0/xx active IP Right Grant
- 1998-07-03 KR KR1020057024112A patent/KR20060002033A/ko not_active Ceased
- 1998-07-03 AU AU83823/98A patent/AU755657B2/en not_active Ceased
- 1998-07-03 CA CA002294737A patent/CA2294737A1/en not_active Abandoned
-
2004
- 2004-08-04 US US10/911,374 patent/US20050003531A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2294737A1 (en) | 1999-01-14 |
| AU8382398A (en) | 1999-01-25 |
| AU755657B2 (en) | 2002-12-19 |
| IL133799A0 (en) | 2001-04-30 |
| US20050003531A1 (en) | 2005-01-06 |
| WO1999001159A1 (en) | 1999-01-14 |
| EP1011732A1 (en) | 2000-06-28 |
| KR20060002033A (ko) | 2006-01-06 |
| EP1011732A4 (en) | 2002-10-23 |
| JP2002515071A (ja) | 2002-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4371179B2 (ja) | 系列限定ニューロン前駆体 | |
| US20130017179A1 (en) | Lineage-Restricted Neuronal Precursors | |
| US7795021B2 (en) | Lineage restricted glial precursors from the central nervous system | |
| JP4848538B2 (ja) | ヒトｃｎｓ神経幹細胞の培養 | |
| US8168174B2 (en) | Method of isolating human neuroepithelial precursor cells from human fetal tissue | |
| JP2001526884A (ja) | 神経前駆細胞、その製造方法および神経性欠陥治療におけるその使用 | |
| CN115463158A (zh) | 诱导多能干细胞衍生的中脑类器官的用途 | |
| US8058063B2 (en) | Method of producing region-specific neurons from human neuronal stem cells | |
| EP1179046B1 (en) | Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells | |
| WO2002014479A2 (en) | Isolated mammalian neural stem cells, methods of making such cells, and methods of using such cells | |
| AU765517B2 (en) | Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells | |
| MXPA00000225A (en) | Lineage-restricted neuronal precursors | |
| US20050186184A1 (en) | Mammalian pluripotent neural cells and uses thereof | |
| Bianco | Stem Cells and Ensheathing Cells from the Nasal Olfactory Mucosa: a Tool for the Repair of the Damaged Spinal Cord |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050701 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050701 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080325 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080625 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080804 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080725 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080916 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081216 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090324 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090624 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090811 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090825 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120911 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130911 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |